Short but dominant.

Similar to short-course radiation alone in the neoadjuvant setting for locally-advanced rectal cancer, this cost effective analysis for the 2022 era confirms short-course radiation as part of total neoadjuvant therapy takes the cake for incurring the least costs while buying the most quality-adjusted life years of any other strategy. | Chin, JAMA Netw Open 2022